Endometriosis

Danazol Offers No Advantage Over No Treatment

Published in Women's Health Weekly, May 31st, 1999

Though long-term postoperative treatment with danazol is effective in women undergoing stage III-IV endometriosis surgery, it shows no significant advantage over expectant management in these patients.

Women who underwent laparoscopic surgery for stage III-IV endometriosis were randomized postoperatively to receive either danazol 600 mg/day for three months or expectant management in a study by S. Bianchi, of the University of Milano, Italy, and colleagues ("Effects of Three Month Therapy with Danazol After Laparoscopic Surgery for Stage III/IV Endometriosis: A Randomized Study," Human Reproduction, May 1999;14(5):1335-1137).

Danazol showed similar...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1999-05-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry